Introduced

Passed House

Passed Senate

Became law

Adjourned sine die. The bill was pending when the session ended, so it did not pass.

Last action · March 5, 2025

Returned To Health Services (H)

Introduced February 19, 2025

House

Adjourned Sine Die

2025 Regular Session

HB788

AN ACT relating to buprenorphine products.

Create a new section of KRS Chapter 311 to require that a dosage regimen for Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone prescribed by a licensed physician to meet the treatment needs of a patient; require the Kentucky Board of Medical Licensure to promulgate administrative regulations to implement the requirement; create a new section of KRS Chapter 314 to require that a dosage regimen for Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone prescribed by a licensed advanced practice registered nurse meet the treatment needs of a patient; require the Kentucky Board of Nursing to promulgate administrative regulations to implement the requirement.

Drugs and Medicines Health and Medical Services Nurses Physicians and Practitioners Substance Abuse Administrative Regulations and Proceedings Boards and Commissions

Read the full text Kentucky Legislature LegiScan

AI-generated. Always verify with primary sources

Plain-language summary

Beta

This bill would require doctors and advanced practice nurses in Kentucky to prescribe buprenorphine — a medication commonly used to treat opioid addiction — in a dosage that meets each individual patient's treatment needs. It directs the Kentucky Board of Medical Licensure and the Kentucky Board of Nursing to create rules carrying out this requirement. Who it may affect: Kentuckians receiving medication-based treatment for opioid use disorder, and the physicians and advanced practice registered nurses who prescribe their care.

Open official bill text (PDF)·Report a problem with the summary